Baxter, Mark A. http://orcid.org/0000-0002-5773-8650
Murphy, John
Cameron, David
Jordan, Judith
Crearie, Christine
Lilley, Christina
Sadozye, Azmat
Maclean, Mary
Hall, Peter http://orcid.org/0000-0001-6015-7841
Phillips, Angela
Greger, Alex
Madeleine, Jude
Petty, Russell D. http://orcid.org/0000-0003-2055-4572
Article History
Received: 11 August 2020
Revised: 6 January 2021
Accepted: 7 January 2021
First Online: 2 February 2021
Change Date: 15 March 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41416-021-01298-w
Ethics approval and consent to participate
: The study was performed with prospective authorisation of the SACT leads from the NHS Scotland Regional Cancer Networks for the provision and use of the data consistent with the networks published information governance frameworks and Caldicott requirements. The study was performed in accordance with the Declaration of Helsinki.
: The authors are committed to the responsible sharing of our research data that is consistent with patient consent, protects the confidentiality and meets the highest standards of integrity and ethics. The data are available upon request to the corresponding author indicating the intended objectives and specific details of the use of data and will only be provided consistent with existing ethical approvals and governance standards in place for the data.
: R.D.P. has undertaken speaking, consulting and advisory roles for Eli Lilly, BMS, Pfizer, Sanofi, Servier, and received research funding (not related to the work in this manuscript) from Astra Zeneca, Roche, MSD, Merck Serrano, Eli Lilly, Five Prime Therapeutics, Clovis, Boston Biomedical and Janssen.
: No specific funding was provided for the work presented in this manuscript.